Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Alessandra Cesano, Scott Storrer, and more

Alessandra Cesano

NanoString Technologies has named Alessandra Cesano its chief medical officer. Cesano brings more than 25 years of experience in drug development, diagnostics, and cancer immunology.

Cesano comes to NanoString from Cleave Biosciences where she served as CMO. She was also CMO and chief operations officer at Nodality. Prior to Nodality, she held various management positions at Biogen Idec, Amgen, and SmithKline Beecham Pharmaceuticals, and positions in academia and tumor immunology research.

Cesano's credentials include an MD, a board certification in oncology, and a PhD in tumor immunology from theUniversityofTurin. She is also a member of the American Association for Cancer Research, the American Society of Clinical Oncology, the American Society of Hematology, the European Hematologic Association, and the Society for Immunotherapy of Cancer.


Scott Storrer

Strand Life Sciences has named Scott Storrer its chief executive office. Earlier this year, he also took on the role of global president for the company.

In his expanded role as president and CEO, Storrer will be responsible for the company's strategy, business expansion, and worldwide operations. He will oversee the continued expansion of Strand's genomics software business and will be responsible for the continued development and marketing of Strand's precision medicine products inIndia.

Vijay Chandru, who has served asStrand's chairman and CEO since the company was founded in 2000, will continue in his role as chairman of the board of directors.


Greg Hannon and Ivan Iossifov

Greg Hannon and Ivan Iossifov have become faculty members of the New York Genome Center.

Hannon joins the center as an associate core member and director of cancer genomics. Previously, he was a professor at Cold Spring Harbor Laboratory. At the NYGC, Hannon will facilitate studies of cancer genomes and will head a research group that focuses on breast cancer and small RNA biology. He holds a BA in biochemistry and a PhD in molecular biology from Case Western Reserve University.

Iossifov will lead ongoing and future large autism sequencing projects at the NYGC and will collaborate with groups within and outside the center on other human diseases. He is a part-time core member and assistant investigator at the center, as well as an assistant professor at Cold Spring Harbor Laboratory. Iossifov holds a PhD in biomedical informatics from Columbia University and a BS and MS in computer science from Sofia University in Bulgaria. 


Kevin Fitzpatrick

Kevin Fitzpatrick has been named CEO of CancerLinQ, a wholly owned non-profit subsidiary of the American Society of Clinical Oncology. 

Fitzpatrick will begin his new role on August 3. In the position, he will be responsible for driving the mission, operations, and ensuring the financial sustainability of CancerLinQ, an SAP HANA-based platform for processing and analyzing data from electronic health records.

Fitzpatrick is currently the executive vice president and chief innovation officer of the American College of Cardiology. Prior to that, he was vice president of business development for Lippincott Williams & Wilkins, a publisher of professional health information resources, managing director of the Duke/Hewlett Packard Center for Outcomes Research, and director of the Trauma Research Laboratory at Duke University Medical Center.


For more recent items on executive appointments and promotions in the omics and molecular diagnostics industries, please see the People in the News page on our website.